Evidence map›Paper›PMID 29108294›Full record

ArticleOncotarget2017

Predicting level 2 axillary lymph node metastasis in a Chinese breast cancer population post-neoadjuvant chemotherapy: development and assessment of a new predictive nomogram.

Caigang Liu, Yanlin Jiang, Xin Gu, Zhen Xu, Liping Ai, Hao Zhang, Guanglei Chen, Lisha Sun, Yue Li, Hong Xu and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Caigang LiuDepartment of Breast Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
Yanlin JiangDepartment of Breast Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
Xin GuDepartment of Head and Neck Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Zhen XuDepartment of Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, the Second Hospital of Dalian Medical University, Dalian, China.
Liping AiDepartment of Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, the Second Hospital of Dalian Medical University, Dalian, China.
Hao ZhangDepartment of Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, the Second Hospital of Dalian Medical University, Dalian, China.
Guanglei ChenDepartment of Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, the Second Hospital of Dalian Medical University, Dalian, China.
Lisha SunDepartment of Surgical Oncology, the First Hospital of China Medical University, Shenyang, China.
Yue LiDepartment of Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, the Second Hospital of Dalian Medical University, Dalian, China.
Hong XuDepartment of Breast Surgery, Liaoning Cancer Hospital & Institute, Shenyang, China.
Huizi GuDepartment of Internal Neurology, the Second Hospital of Dalian Medical University, Dalian, China.
Ying YuLiaoning Medical Device Test Institute, Shenyang, China.
Yangyang XuDepartment of Urinary Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Qiyong GuoDepartment of Radiology, Shengjing Hospital of China Medical University, Shenyang, China.
Second Affiliated Hospital of Dalian Medical University · CNChina Medical University · CNHarbin Medical University · CNDalian Medical University · CNLiaoning Cancer Hospital & Institute · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe aimed to develop a new nomogram to predict the probability of level 2 axillary lymph node metastasis (L-2-ALNM) in breast cancer (BC) patients treated with neoadjuvant chemotherapy (NAC).

methodsData were collected from 709 patients who received neoadjuvant chemotherapy and then underwent axillary lymph node (ALN) dissection between May 2009 and December 2015 at the Liaoning Cancer Hospital. The level 2 axillary lymph node metastasis (L-2-ALNM ) nomogram was created from the logistic regression model. An additional set of 141 consecutive patients treated at the same institution between January 2015 and December 2015 were enrolled as the validation group. The predictive accuracy of the L-2-ALNM nomogram was measured by calculating the area under the receiver operating characteristic curve (AUC).

resultsIn multivariate analysis, age, tumor size, histological grade, skin invasion, and response to neoadjuvant chemotherapy were identified as independent predictors of L-2-ALNM. The new model was accurate and discriminating for both the modeling and validation groups (AUC: 0.819

conclusionThe L-2-ALNM nomogram shows reasonable accuracy for making clinical decisions. The omission of level 2 axillary lymph node dissection after neoadjuvant chemotherapy might be possible if the probability of level 2 lymph node involvement was < 10% or < 20% in accordance with the acceptable risk determined by medical staff and patients.

Indexed as

breast cancerlevel 2 axillary lymph node dissectionlevel 2 axillary lymph node metastasisneoadjuvant chemotherapynomogram

Identifiers

PMID29108294
PMCPMC5668027
OpenAlexW2599182962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.